JOHNSON & JOHNSON ANNOUNCES ICOTYDE® (ICOTROKINRA) DELIVERS SIGNIFICANT IMPROVEMENT IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AMONG BIOLOGIC-NAIVE PATIENTS WITH ONCE-DAILY TARGETED ORAL PEPTIDE

Reuters · 3d ago

Please log in to view news